Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma

Annals of Oncology

Volumn 14, Issue 4, 2003, Pages 638-642

  Hess, V ^a   Verrill, M W ^a   Bomphray, C C ^a   Vaughan, M M ^a   Allen, M ^a   Gore, M E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Carboplatin; Doxorubicin; Ovarian carcinoma; Weekly paclitaxel

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REMISSION; TIME; TREATMENT PLANNING; CARCINOMA; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; MIDDLE AGED; NEUTROPENIA; OVARY TUMOR; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 0037481741     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg176     Document Type: Article

References (25)

1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cis-platin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
2. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708.
3. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084-3092.
4. du Bois A, Luck HJ, Meier W et al. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Semin Oncol 1997; 24 (Suppl 15): 44-52.
5. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus Cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991; 9: 1668-1674.
6. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726-732.
7. ICON Collaborators. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (Cyclophosphamide, doxorubicin and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study. Lancet 1998; 352: 1571-1576.
8. Naumann RW, Alvarez RD, Omura GA et al. A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancer. Gynecol Oncol 1998; 71: 450-453.
9. Hill M, Macfarlane V, Moore J, Gore ME. Taxane/platinum/anthracycline combination therapy in advanced epithelial ovarian cancer. Semin Oncol 1997; 24 (Suppl 2): 34-37.
10. Gregory RK, Hill ME, Moore J et al. Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy. Eur J Cancer 2000; 36: 503-507.
11. Kristensen G, Vergote I, Stuart G et al. First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynecological Cancer Intergroup phase III trial. Proc Am Soc Clin Oncol 2002; 21: 202a (Abstr 805).
12. Pfisterer J, Weber B, du Bois A et al. Epirubicin/paclitaxel/carboplatin vs. paclitaxel/carboplatin as first-line treatment in ovarian cancer: results of a safety interim analysis of the AGO-GINECO intergroup trial. Proc Am Soc Clin Oncol 1999; 18: 367a (Abstr 1418).
13. Fennelly D, Aghajanian C, Shapiro F et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187-192.
14. Seidman AD. One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index. Oncology (Huntingt) 1998; 12: 19-22.
15. Andersson H, Boman K, Ridderheim M et al. Updated analysis of a randomized study of single agent paclitaxel given weekly vs every 3 weeks to patients with ovarian cancer treated with prior platinum therapy. Proc Am Soc Clin Oncol 2000; 19: 380a (Abstr 1505).
16. Kohn EC, Sarosy G, Bicher A et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18-24.
17. Kohn EC, Sarosy GA, Davis P et al. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Gynecol Oncol 1996; 62: 181-191.
18. du Bois A, Luck HJ, Bauknecht T et al. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. J Clin Oncol 1999; 17: 46-51.
19. Papadimitriou CA, Moulopoulos LA, Vlahos G et al. Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study. Cancer 2000; 89: 1547-1554.
20. Lau DH, Xue L, Young LJ et al. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999; 14: 31-36.
21. Markman M, Hall J, Spitz D et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002; 20: 2365-2369.
22. Fleming GF, Fowler JM, Waggoner SE et al. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19: 1021-1029.
23. Gianni L, Vigano L, Locatelli A et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906-1915.
24. Aapro M, Bolis G, Chevallier B et al. An EORTC-GCCG randomized phase II trial of doxorubicin versus doxorubicin-cisplatin in endometrial carcinoma. Proc Am Soc Clin Oncol 1994; 13: 275 (Abstr 885).
25. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62: 278-281.